The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is seeking parties interested in co-development or licensing a substrate reduction therapy for Smith-Lemli-Opitz Syndrome (SLOS) and other diseases which have a secondary Niemann-Pick type C disease like cellular phenotype.
The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks licenses and/or co-development partners for methods of treating cancer by administering PIKFYVE inhibitors and P38 MAP kinase inhibitors.
In collaboration with the National Cancer Institute (NCI), researchers at The Eunice Kennedy Shriver National Institute on Child Health and Human Development (NICHD) have discovered monoclonal antibodies that bind to matrilin-3, a protein specifically expressed in cartilage tissue, that could be used for treating or inhibiting growth plate disorders, such as a skeletal dysplasia or short stature. The monoclonal antibodies can also be used to target therapeutic agents, such as those for anti-arthritis, to cartilage tissue. NICHD seeks statements of capability or interest from parties interested in collaborative research to co-develop, evaluate, and/or commercialize treatment of skeletal disorders using targeting antibodies.
Investigators from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) have identified five autophagy-inhibiting compounds (WX8 family) through a high-throughput screening. The NICHD seeks licensees and/or co-development partners for methods to treat cancer by administering these autophagy-inhibiting compounds.
The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks licensees for a novel “EpiTag” epigenetic reporter transgenic zebrafish line that provides a versatile and powerful whole-animal platform for visualizing and assessing the effects of mutants, experimental treatments, or chemical compounds targeting epigenetic regulation as well as studying epigenetic regulation of global- or tissue-specific gene expression during development.
The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks research partners, co-development partners, and/or licensees for hydrogels that can be used in tissue repair. Gels typically exhibit a decrease in mechanical strength (e.g., elastic modulus) upon swelling of the particles. The gels of this technology, however, exhibit an increase in mechanical strength upon swelling. The gels are comprised of a crosslinked polymer matrix dispersed in a crosslinked polymer matrix.